Since the introduction of the corticosteroids, there has been a continuing search for newer compounds which would have equal or greater therapeutic efficacy and which would produce fewer adverse reactions in patients on prolonged maintenance therapy. The Δ1 analogues of cortisone and hydrocortisone (prednisone and prednisolone) have been the most active of the available corticosteroids. Moreover, with these drugs, the incidence of sodium retention, excessive potassium depletion, and hypertension has been considerably reduced.
The purpose of this clinical study was to evaluate the anti-inflammatory and antipruritic properties of a new steroid compound, Aristocort diacetate (also known as triamcinolone diacetate), in a variety of severe dermatological disorders. The formula of this new steroid is Δ1 9a-fluoro-16a-hydroxy-hydrocortisone-diacetate, and it was synthetized by Bernstein and others.1 Animal assays indicate that this compound will not produce sodium retention and that it is 18 to 36 times more potent than hydrocortisone in
Rein CR, Fleischmajer R, Rosenthal AL. USE OF A NEW CORTICOSTEROID (ARISTOCORT DIACETATE) IN DERMATOLOGY. JAMA. 1957;165(14):1821–1823. doi:10.1001/jama.1957.72980320003011a
Customize your JAMA Network experience by selecting one or more topics from the list below.